All In Biotech

Drug Trial Radar · NCT06649747

Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain

A Double-blind, Placebo-controlled, Multi-center Phase II Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Oral AFA-281 in Patients With Painful Lumbosacral Radiculopathy

Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

408

Planned (sponsor's estimate)

Start

Apr 1, 2027

Primary completion

Mar 31, 2032

Study completion Mar 31, 2032

Sponsor

Lead sponsor
Afasci IncIndustry
Sponsor type
Industry
First posted
Oct 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate if the drug candidate AFA-281 works to treat chronic low back and leg pain caused by painful lumbosacral radiculopathy (PLSR) in adults. This trial will also evaluate the safety of AFA-281. The main questions it aims to answer are: * Does AFA-281 mitigate pain? * What are the side effects (if any)? Researchers will compare AFA-281 to a placebo (a look-alike substance that contains no drug) to see if AFA-281 works to treat chronic low back and leg pain. Participants will: * Take drug AFA-281 or a placebo three times every day for 4 weeks * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their pain scores and about mood and sleep questionnaires, and the number of times they use a rescue pain medicines.

Conditions

  • Lumbosacral Radiculopathy

Interventions

  • AFA-281Drug

    A small molecule, orally available

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numeric Pain Rating ScaleTime frame: 2 weeks baseline and 4 weeks of treatment, and 2 weeks after the end of treatment
  2. Safety- Number of Participants with Treatment-Related Adverse Events (AEs)Time frame: Baseline (2 weeks) and 4 weeks of the treatment, and 4 weeks of followup

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.